Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with high-grade serous epithelial ovarian cancer, confirmed by a biopsy
• People whose cancer is at stage III or IV and for whom doctors have determined that chemotherapy before surgery (neoadjuvant chemotherapy) is the appropriate treatment plan
• People whose tumor tests positive for a specific protein called folate receptor alpha (FRα), found in more than 75% of tumor cells at a certain level of intensity
• People who are able to provide a stored tumor tissue sample, or who are willing to have a new biopsy taken using a routine, low-risk procedure, so that the FRα protein level can be confirmed
• People who have a good general level of physical functioning, rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
• People whose blood, liver, and kidney test results fall within acceptable ranges as defined by the trial (confirm with trial site for specific values)
• People who are willing and able to sign a consent form and follow the requirements of the trial
• Women who could become pregnant must agree to use highly effective contraception during the trial treatment and for at least 4 months after the last dose
• Women who could become pregnant must have a negative pregnancy test within 4 days before the first dose of the trial treatment

Who may not be able to join:

• People who have previously received any systemic cancer treatment
• People whose ovarian cancer is of a different type, specifically low-grade serous, endometrioid, clear cell, or mucinous
• People with active or long-term eye conditions, a history of corneal transplant, or ongoing eye conditions such as uncontrolled glaucoma, certain forms of macular degeneration, active diabetic eye disease, swelling of the optic nerve, or vision in only one eye
• People with a history of hepatitis B or hepatitis C infection, regardless of whether they are currently on antiviral treatment
• People with a history of HIV infection
• People who have required intravenous (IV) antibiotics for an active infection within the 2 weeks before the first treatment dose
• People with a history of multiple sclerosis or other diseases that affect the protective coating of nerves, or a condition called Lambert-Eaton syndrome
• People with significant heart conditions, including a heart attack within the past 6 months, unstable chest pain (angina), poorly controlled heart failure, high-grade uncontrolled high blood pressure, or uncontrolled irregular heart rhythms
• People who have had a stroke (either bleeding or blockage type) within the 6 months before enrolling
• People with a history of significant liver scarring (cirrhosis) classified as Child-Pugh Class B or C
• People with a history of non-infectious lung inflammation, including a condition called noninfectious interstitial lung disease or pneumonitis
• People who need to take folate (folic acid) supplements, for example due to folate deficiency
• People who have had a severe allergic reaction to monoclonal antibody treatments in the past
• Women who are pregnant or breastfeeding
• People who have previously been treated with the trial drug (MIRV) or any other treatment that targets the FRα protein
• People whose cancer has spread to the brain or nervous system and is either untreated or causing symptoms
• People who have had another cancer diagnosed within the past 3 years — though people with certain very low-risk skin cancers or early-stage cancers that have been adequately treated may still be considered eligible (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.